

Nottinghamshire Area Prescribing Committee

Nottinghamshire Heart Failure Guidelines

Primary Care Referral and Management Considerations

Author: Dr Bara Erhayiem, Consultant Cardiologist, Nottingham University Hospitals NHS Trust with input from the Heart Failure Transformation Group

Nottinghamshire Heart Failure Guideline Version 1.0 Approved: February 2025. Review: February 2028. Accessibility checked - contains flow charts and tables that may not be accessible to screen readers.



Contents

Contacts NUH&SFH Scope and Purpose Diagnosis of Heart Failure Referral & Service Structure Urgent Referral Criteria General Principles of Care Treatment of Heart Failure with Reduced Ejection Fraction Treatment of Heart Failure with Preserved Ejection Fraction Diuretic Management Drug Dosing: Core Heart Failure Therapies Drug Dosing: Adjunct Heart Failure Therapies Advanced Heart Failure and Palliation

Page 3&4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 13 Page 14 Page 15 Page 16



Contacts for NUH

There are several routes into getting specialist heart failure advice in Nottingham. In addition to a patient's named cardiologist, there is a specialist heart failure team comprising of heart failure cardiologists and heart failure specialist nurses. Prompt advice can be given through the regular heart function MDT, email or through heart failure clinics.

Nottingham heart failure specialist consultant team: Drs Bara Erhayiem, Amar Mistry, Jenny Chuen and Saima Khan

Heart failure MDT referrals via: Community and NUH heart failure nurse specialist team

HF team above, and on-call cardiology team, via switchboard:

Queens Medical Centre (0115 9249924) City Hospital Campus (0115 9691169)

For non-urgent, simple, enquiries regarding patients not known to NUH cardiology, the 'Advice & Guidance' (A&G) system can also be used.

NUH heart failure and general cardiology clinics:

Referrals into the NUH service can be made via 'Electronic Referral System' (ERS). The patient will be vetted to one of many clinical services depending on the clinical urgency.

Community Heart Failure Nurse Specialists:

Nottingham North and West and North and East: 0300 0830000 Rushcliffe: 0115 8440504 City: 0300 300 7995

Nottinghamshire Heart Failure Guideline Version 1.0 Approved: February 2025. Review: February 2028. Accessibility checked - contains flow charts and tables that may not be accessible to screen readers.



Contacts for SFH

Referrals into the SFH service can be made via 'Electronic Referral System' (ERS). The patient will be vetted to one of many clinical services depending on the clinical urgency:

- HF Consultant Advice & Guidance
- General Cardiology Clinic
- One Stop Heart Failure Clinic
- Community HF Nurse Service MDT care

Heart Failure Lead Consultant Cardiologist: Dr Ifti Fazal

Heart Failure Specialist Nurse Team Gail Moore, Lynsay Hayes

HF team above, and on-call cardiology team, via Sherwood Forest Hospitals switchboard: 01623 622515

Community Heart Failure Nurse Specialists: Newark & Sherwood: 01623 781891 Mansfield & Ashfield: 01623 781891





Scope and Purpose

The purpose of these guidelines is to provide local clinical and service guidance for primary and secondary care on the diagnosis, management, and referral of patients with or suspected of having heart failure. The guidelines have been developed through the Nottingham Heart Failure Transformation Group and using the latest clinical research, evidence, and NICE/ESC guidance, considering our local structure, logistics and capacity.

These guidelines are not a comprehensive overview of epidemiology, budget, targets, pathophysiology, and very advanced care considerations. They are also not a detailed overview into the teaching and reference of heart failure signs, symptoms, and clinical features. The aim is for supporting healthcare professionals in recognising heart failure, urgency of referrals and expediently implementing the best-evidenced treatment in an equitable manner to help care for this very high-risk population.

The definition of 'specialist' in this guideline is any healthcare professional who has undertaken an appropriate formal qualification or period of recognised training in heart failure or cardiology and has working experience and knowledge in this area. It includes cardiologists, specialist nurses, pharmacists, HCOP physicians with interest in heart failure and GPs with interest in heart failure. By adhering to this guideline when prescribing for heart failure patients and indications, it is assumed that any Notts APC requirements for drug prescribing are met.


Resource Links:


British Society for Heart Failure: <u>https://www.bsh.org.uk/</u> NICE guideline: <u>https://www.nice.org.uk/guidance/ng106</u> ESC guidance: <u>https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Focused-Update-on-Heart-Failure-Guidelines</u> Cardiorenal Forum: <u>https://www.cardiorenalforum.com/</u> Notts APC HF palliative guideline: <u>https://www.nottsapc.nhs.uk/media/3gvbware/palliative-care-in-end-stage-heart-failure.pdf</u>



Diagnosis


Clinical signs & symptoms that are suspicious of heart failure







Referral & Service Structure NUH&SFH



Approved: February 2025. Review: February 2028.

Accessibility checked - contains flow charts and tables that may not be accessible to screen readers.



Referral Criteria

Working diagnosis of clinical heart failure & prior to echocardiography

Urgent clinical criteria for priority referral	Urgent management considerations at time of initial GP practice assessment		
 NTproBNP criteria in the absence of significant life-limiting extra- cardiac co-morbidity NTproBNP > 600ng/L if age < 50 NTproBNP > 2000ng/L if age < 75 	Offer loop diuretics if evidence of peripheral oedema, ascites, pleural effusions or raised JVP		
• NTproBNP > 2000ng/L if age >75 and in sinus rhythm Consider reducing the cut-off levels by 50% in BMI > 40 and in patients on ACEi/ARB.	Offer ACE-inhibitor or angiotensin receptor blocker if has hypertension, CKD with proteinuria and/or diabetes		
Suspicion of severe valve disease on auscultation	In existing CKD or Type II diabetes patients only - Consider SGLT2 inhibitor if eGFR >30mL/min.		
Left Bundle Branch Block on ECG with QRS duration >150ms	Do not add Beta blockers prior to seeing echo results – it		
Oedema past thighs limiting mobility	can be clinically dangerous to prescribe without a diagnosis		
Syncope on exertion and/or with no prodrome	Stop non-prognostic therapies if blood pressure normal or		
Pregnancy or wanting to become pregnant soon	low; oral nitrates, calcium-channel, and alpha blockers		
Awaiting urgent surgery (non-cardiac)	Stop or switch therapies that are harmful in heart failure,		
Awaiting or undergoing potentially curative Cancer treatment	including regular NSAIDs, glitazones, rate-limiting calcium- channel blockers (diltiazem and verapamil), venlafaxine.		
eGFR < 30mL/min	Strongly advise to reduce excess alcohol consumption, stop		
Symptomatic hypotension or bradycardia	smoking, and limit excess dietary salt intake		



General Principles of Care

	Avoid sedentary behaviour.
For all patients	Encourage physical exercise appropriate to baseline fitness.
	Avoid excess salt intake.
	Avoid excess fluid intake but do not routinely advise long-term fluid restriction.
	Avoid excess alcohol intake.
	Smoking cessation advice.
	Optimisation of co-morbidities.
	Advise 'Think Kidney' campaign and sick-day rules for ACE-i/ARB/SGLT2i temporary cessation.
	Diuretic education.
For patients on pre- existing cardiac medicines	It is appreciated that many new HFrEF patients may already be on medicines for angina, hypertension, chronic kidney disease. 1. continue pre-existing ACE-i or ARB or up-titrate if on low dose.
for previous non-heart	2. If not on a beta-blocker licensed for HFrEF, switch to the equivalent dose of bisoprolol.
failure indications	3. Focus on the addition of new HF therapies to complete 'quadruple' care, rather than titration alone of pre-existing medicines. See next page
	4. Convert CVD primary prevention statin dosing to secondary prevention dosing if myocardial infarction suspected on echocardiogram.
For patients with type II	1. Refer to T2DM guidance, taking into account most recent HbA1c and usual glucose levels.
diabetes on insulin and/or sulphonylurea when being	2. If diabetes is already well controlled, consider stopping sulphonylurea and consider reducing insulin by 10% as you start SGLT2i
initiated onto SGLT2i	3. Seek advice from diabetes specialist nurse, community HF team or NUH HF team if unsure rather than not offer SGLT2i.
Community speciality referrals	 HFrEF: Community heart failure team referrals to support ongoing cardiac therapy titrations and MDT support. HFpEF: If available, community matron team referral to support co-morbidity, frailty and/or diuretic management. Community palliative care team for advancing heart failure and co-morbidity: see page 16. Heart failure, pulmonary or cardiac rehabilitation referral for all patients, as available. Community HCOP referral for patients with significant frailty and co-morbidities.



HF with reduced LVEF

Start 'quadruple' therapy in all patients with a left ventricular ejection fraction $\leq 40\%$, if no *absolute* contraindications and as soon as possible, by *GP practice in conjunction with community HF teams.*

atient Profile	Starting Medications and dosing	Therapy guidance
	Bisoprolol 1.25mg OD	All therapies can start simultaneously at lowest doses and
stolic blood pressure >	Losartan 25mg (ARB) or ramipril 1.25mg (ACE-i)	-side effect profiles are usually easily identifiable
0mmHq	Spironolactone 25mg (MRA) OD	-this adds prognostic and symptomatic benefit.
art rate > 60bpm	Dapagliflozin or Empagliflozin 10mg (SGLT2i) OD (Seek	Reduce loop diuretics if the patient is not fluid overloaded
ormal Sodium and	specialist advice to approve initiation outside of T2DM and CKD.	Try to delay beta-blocker until severe fluid overload improving.
	This may include specialists within your practice or PCN or via	Clinically review within 2 weeks (inc. U&E and BP/HR)
tassium	A&G from cardiology if no local HF specialist.)	An initial eGFR reduction of up to 33% can occur. >33% consider renal artery
iFR > 30mL/min		stenosis (outside of dehydration or worsening HF)
ready on stable ACE-	Consider Sacubitril/Valsartan instead of ACE-i/ARB	
RB	up-titration	Cardiologists or community HF specialists may advise to start sacubitril/valsartan
	Entresto 24/26mg BD (specialist initiation/advice)	early or first-line in selected patients (this may include specialists from the
0mmHg		practice/PCN).
uning	ACEi therapy must be discontinued at least 36 hours before	
	initiation of sacubitril/valsartan due to risk of angioedema from	Clinically review within 2 weeks
	concurrent therapy.	For U&E, oedema and BP/HR check
resting heart rate <	Do not offer a beta-blocker	Continue with initiating other therapies as indicated
lbpm		
	Avoid initial ACE-i/ARB and beta-blocker	Clinically review within 2 weeks (inc. U&E and BP/HR) for ACE-i/ARB or beta-
ymptomatic low blood	Avoid sacubitril/valsartan	blocker.
pressure or postural	Give: -Spironolactone 25mg OD	
hypotension	-SGLT2s: Dapagliflozin or Empagliflozin 10mg OD (Seek	At these doses, SGLT2i and MRA do not cause hypotension.
nypotension	specialist advice to approve initiation outside of T2DM and CKD.	
	Includes specialists within your practice/PCN)	
eGFR < 30mL/min	Avoid starting ACE-i/ARB, MRA and SGLT2i	Early Secondary Care opinion needed via referral or Advice&Guidance.
	Give Bisoprolol 1.25mg OD	
Potassium > 5.5mmol/L	Avoid starting ACE-i/ARB and/or MRA	Clinically review within 2 weeks (inc. U&E and BP/HR)
	Give Bisoprolol 1.25mg OD	
	Give Dapagliflozin or Empagliflozin 10mg OD (Seek specialist	Advise low potassium diet.
	advice to approve initiation outside of T2DM and CKD. Includes	
		Early HF team opinion if persistently raised
	Aim to maintain patient on the lowest dose of loop diu	uretic required to maintain comfortable euvolaemia.
		eraction to avoid hypovolaemia/dehydration.



Points

2

1

1

1

1

HF with preserved LVEF

The evidence for blanket prognostic therapies in left ventricular ejection fraction >45% is lacking and rapid 'quadruple' therapy is not advised and may even be harmful.

Diagnostic criteria for classic 'HFpEF'

Clinical features of heart failure with raised NTproBNP, dilated atria and/or left ventricular hypertrophy (LVH) on echocardiography. Further refinement can be made utilising clinical scoring systems like H2FPEF (opposite).

Treatment

For patients with confirmed HFpEF, the main goals of treatment are to reduce symptoms, increase functional status, and reduce the risk of hospitalisation. At present, there is no clear evidence that any specific pharmacological therapy, diet, or other treatments reduce the risk of mortality.

Early recognition and treatment of fluid overload improves symptoms and may prevent a requirement for hospitalisation.

Conditions commonly associated with HFpEF include -atrial fibrillation.

-hypertension,

-coronary artery disease,

- -COPD,
- -anaemia.

-chronic kidney disease, -sleep-disordered breathing. Screening for and treatment of these co-morbidities is particularly relevant in HFpEF where the comorbidity burden is often high and drives additional

-diabetes.

healthcare needs and non-HF related hospitalisations.

On the following page, there are management considerations to consider in all patients with HFpEF that may influence specialist referral and specific treatments.

 H_2 Hypertensive 2 or more antihypertensive medicines F Atrial Fibrillation Paroxysmal or Persistent 3 Doppler Echocardiographic estimated Pulmonary P Pulmonary Artery Systolic Pressure > 35 **Hypertension** mmHa E Elder Age > 60 years F Filling Pressure Doppler Echocardiographic E/e' > 9 Sum H₂FPEF score (0-9)**Total Points** 8 Probability of HFpEF 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.95

Values

Body mass index > 30 kg/m²

Clinical Variable

Heavy

Approved: February 2025. Review: February 2028.

Accessibility checked - contains flow charts and tables that may not be accessible to screen readers.



Patient Profile in suspected HFpEF	Diagnosis Consideration	Management Guidance
Obesity Metabolic syndrome Type II diabetes Atherosclerotic vascular disease Smoking history Chronic kidney and/or liver disease Elderly COPD	Classic and highly likely 'HFpEF'	Offer Dapagliflozin or Empagliflozin 10mg OD to all (seek specialist advice to approve initiation outside of CKD and T2DM; this may include specialists from the practice/PCN) - if eGFR > 20mL/min; Avoid beta-blockers unless a strong non-HF indication. Diuretic titration to maintain euvolaemia (including reducing if the patient is not fluid overloaded) Spironolactone 25mg OD: especially if HTN or obesity. Reduction of polypharmacy. Conservative blood pressure targets for hypertension. Physical rehabilitation and regular aerobic activity Screen for COPD and Obstructive Sleep Apnoea if concerns
Persistent/Permanent Atrial fibrillation	Common finding, especially in the elderly	Digoxin preferred , if needed, in HFpEF. Consider weaning off beta-blockers if heart rate < 70bpm. No strict target heart rate: aim <110bpm at rest.
No typical HFpEF comorbidities and age <40 to 65	Possible HFpEF	Early cardiology referral
Any patient age < 40 +/- positive family history +/- features of shunt +/- features of pulmonary hypertension +/- normal ECG	Classic HFpEF very unlikely Needs specialist input and workup	Early cardiology referral
History of carpal tunnel syndrome Small QRS complexes on ECG despite LVH on echo Autonomic and peripheral neuropathy Heavy proteinuria / Nephrotic Sensitive to BP lowering medications Myeloma/MGUS history	Cardiac Amyloidosis	Early cardiology referral if no suspicion of myeloma and Cardiac amyloidosis suspected. Urgent free-light chains and immunoglobulins recommended Urgent referral to Haematology if myeloma suspected
Previous TB, pericarditis, or cardiac surgery Previous chest radiotherapy Severe fluid overload with NTproBNP <1000ng/L Ascites, liver dysfunction with normal albumin Raised venous pressures with 'normal' echo	Constrictive Pericarditis	Early cardiology referral for advanced imaging



Diuretic management

 > 95% of patients are fluid overloaded at time of heart failure diagnosis Loop diuretics are the mainstay of treatment. Falling eGFR and low sodium are common findings in fluid overload care has to be taken to not misinterpret these findings as reason to not offer diuresis. As heart function therapies are initiated, the need for diuretics frequently reduces and diuretics should be wean down to lowest possible maintenance dose at every opportunity to avoid hypovolaemia, hypotension and pre-renal acute kidney injury. An increase in diuretic should be considered when: Increase in weight of ≥2kg over 2-3 days. Increase in diuretic should be considered when: Stable and mild dyspnoea with no oedema, ascites, orthopnoea. 	Diuretic prescribing guidance Furosemide 20-40mg once to twice daily, titrating as needed up to 120mg BD If still symptomatic and on 120mg twice daily of furosemide, consider switching to bumetanide, which has greater and more consistent bioavailability. 40mg furosemide = 1mg bumetanide If sodium > 135mmol/L, early supplementation with bendroflumethiazide or metolazone 2.5mg to 5mg 'PRN' from once weekly to once daily at midday. Metolazone is classified Red - only for specialists to prescribe. Ensure on SGLT2i if no contraindication. In patients on ACEi/ARB - Increase Spironolactone or Eplerenone to 50mg once daily. Eplerenone is classified Amber2 – specialist recommendation/initiation. In patents NOT ON ACEi/ARB Spironolactone to 200mg daily without the presence of other prescription.		
and decreased skin turgor, postural hypotension).	Ensure no excess dietary salt intake and no excess fluid intake.		
U&E should be repeated within 1-2 weeks of diuretic dose changes.	Aim sodium >125mmol/L if symptoms improved and oedema controlled		
It is encouraged to empower patients and teach them to record their own weight and symptoms frequently and self-titrate loop diuretics. The routine advice for fluid restriction is not encouraged by any guideline and can be harmful. Patients should be encouraged to control dietary salt and fluid excess .	Referral for intravenous ambulatory furosemide If an ambulant community HF patient has increasing symptoms and fluid overload despite >120mg furosemide or >3mg bumetanide twice-daily, then please urgently call the 'NUH heart failure team' via NUH switchboard to consider day-case unit attendance for ambulatory intravenous furosemide therapy (SFH does not provide day-case unit attendance for ambulatory IV furosemide).		



Drug Dosing: core therapies

Heart Failure Medication	Starting Target Dose		Titration steps	Ensure			
	Dose			Heart Rate > 50bpm	Systolic BP > 110mmHg	Potassium <5.5mmol/L	eGFR reduction <33%
Beta-blocker: Bisoprolol	1.25mg once daily	10mg once daily Or 5mg BD if OD not tolerated	1.25mg - increase every 2 wks	\checkmark	\checkmark		
ACE-inhibitor: Ramipril	1.25mg once daily	10mg once daily Or 5mg BD if OD not tolerated	1.25mg - increase every 2 wks		\checkmark		
Angiotensin Receptor Blocker (ARB): Losartan	25mg once daily	150mg once daily	50mg - increase every 2 wks		\checkmark	\checkmark	\checkmark
Aldosterone Antagonist (MRA): Spironolactone or Eplerenone (Amber2)	25mg once daily	50mg once daily	25mg - increase at 2-4 wks		Doesn't cause hypotension at these doses		
SGLT2 inhibitor: Dapagliflozin or Empagliflozin (Amber2 for HF) (Amber3 for CKD/T2DM)	10mg once daily	10mg once daily	NB Do not give in Type I Diabetes		Does not cause hypotension at these doses		
Neprilysin inhibitor and ARB: Sacubitril/ Valsartan (Amber2)	24/26mg twice daily	97/103mg twice daily	Double dose every 2-4 weeks		\checkmark		




Heart Failure: adjunct therapies

Heart Failure Medication	Indication	Starting Dose	Titration or referral steps
Ivabradine	Symptomatic HF with LVEF < 35% On maximal tolerated beta-blocker Sinus rhythm Heart rate > 75bpm and BP > 90mmHg	Seek specialist opinion first. 2.5mg twice daily	2.5mg increase every 2-4 weeks Target heart rate 50 to 75bpm Ensure systolic BP > 90mmHg Maximum dose 7.5mg twice daily
Digoxin	Worsening HF despite optimal therapy Whether patient in AF or sinus rhythm	Seek specialist opinion if in sinus rhythm. 62.5mcg once daily if in AF	Maintenance dose usually 125mcg OD
Nitrate / Hydralazine	Worsening HF despite optimal therapy Especially if of African/Caribbean origin And/or ACE-i/ARB dosing limitation if CKD 4-5 And/or if severe hypertension	Seek specialist opinion first. ISMN MR 30mg once daily Hydralazine 25mg three times daily	Titrate to symptoms; maximum dosing ISMN MR 120mg once daily Hydralazine 75mg three times daily
Potassium Binder: Sodium Zirconium Cyclosilicate	If persistent hyperkalaemia and have serum potassium of at least 6.0 mmol/L Despite low potassium diet If limiting ACE-i/ARB/MRA optimisation	Seek specialist opinion first. 10g three times daily loading dose 5g once daily starting dose Specialists may consider early initiation, before potassium reaches 6mmol/L, in selected patients.	Titrate to potassium levels; Maintenance dose range: 5g alternate day to 10g once daily
Intravenous Iron	Symptomatic HF with LVEF < 45% Ferritin <100mcg/L Ferritin 100 to 300mcg/L if TSATs < 20%	N/A	IV Iron Referral Form to NUH HF Team Refer for IV Iron to KMH via Community HF Nurses. Ensure bone profile and vitamin D checked.



Advanced Heart Failure



1. NTproBNP above 1000pg/ml after 90 days of optimal treatment; 2. Serum Creatinine increase by 27mmol/L; 3. Heart Failure Hospitalisation within last six months; 4. Furosemide above median dose of 80mg daily; 5. Systolic BP <100mmHg; 6. For circulatory-renal reasons

The typical illness trajectory for heart failure is a gradual functional decline with intermittent episodes of decompensation which may mean that death may appear 'sudden'.

Prognostication can be difficult and needs to be personalised with each patient. What can also be difficult to predict is reversibility after a specific therapy is initiated, e.g. medicine combinations, pacemaker device and/or coronary revascularisation. Good communication with the heart failure team is essential so that symptomatic and/or prognostic intervention can be appropriately considered - or indeed, so that important timely reverse-titration of therapy can be advised.

Patients benefit from palliative care given alongside active care.

Two of the following conditions could indicate that a patient may be included within your Palliative Care Register:

1) Severe breathlessness despite optimal medical therapy

2) Question: "I would not be surprised if this patient died in the next 6-12months"?

3) Repeated heart failure hospital admissions:

4) Difficult physical or psychological symptoms despite optimal tolerated therapy

The opposite diagram showing the "I NEED HELP" acronym is a useful aidememoir.

Notts APC HF palliative guideline:

https://www.nottsapc.nhs.uk/media/3gvbware/palliative-care-in-end-stage-heart-failure.pdf

Nottinghamshire Heart Failure Guideline Version 1.0

Approved: February 2025. Review: February 2028.

Accessibility checked - contains flow charts and tables that may not be accessible to screen readers.